Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]

SARS-CoV-2 IgM ELISA Kit

For identifying the early immune response to SARS-CoV-2 infection

WARNING: This product can expose you to chemicals including TMB, which is known to the State of California to cause cancer, and Ethylene glycol, which is known to the State of California to cause birth defects or other reproductive harm.  For more information go to  www.P65Warnings.ca.gov.
Catalog #: E4902
$695.00

Product Details

Cat # +Size E4902-100
Size 100 assays
Kit Summary BioVision’s SARS-CoV-2 IgM ELISA Kit is an enzyme-linked immunosorbent assay intended for identifying the early immune response to SARS-CoV-2 infection. The assay uses the spike protein S1 subunit as bait to capture anti-SARS-CoV-2 antibodies in diluted plasma or serum samples. Subsequent reaction with an enzyme-labeled anti-human-IgM conjugate and a colorimetric substrate generates color, which is proportional to the amount of anti-S1 antibodies. The presence of anti-SARS-CoV-2 S1 IgM antibodies is determined by comparing the OD450 nm reading of the sample to the OD450 nm reading of the negative control serum. A positive reaction suggests recent infection, as IgM antibodies are the first to appear following exposure and are generally detectable a few days after infection. Positive control serum containing a recombinant human monoclonal anti-S1 IgM antibody is included in the kit for validation. The assay is a quick, easy and accurate method for determination of recent SARS-CoV-2 infection that does not require collection or handling of infectious virus. This kit is a valuable tool to study COVID-19 epidemiology, prevalence and morbidity.
Detection Method Absorbance at 450 nm
Species Reactivity Human
Applications • Study of epidemiology, prevalence and morbidity of COVID-19
• Screening of SARS-CoV-2 infection rate in a given population
• Determination of recent/prior SARS-CoV-2 infection
Features & Benefits • A valuable tool to study COVID-19 epidemiology, prevalence and morbidity.
• The assay is a quick, easy and accurate method for determination of recent SARS-CoV-2 infection.
• The assay does not require collection or handling of infectious virus.
Kit Components • Spike Protein-Coated ELISA Plate
• Wash Buffer (10X)
• Sample Diluent
• Anti-IgM-HRP Conjugate (500X)
• Positive Control Serum
• Negative Control Serum
• TMB Substrate
• Stop Solution
• Plate Sealing Film
Storage Conditions -20°C
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.

Details

Coronaviruses are large, lipid-enveloped, single-stranded RNA viruses known to infect a wide array of hosts, including humans, bats, mice and other mammals. Amongst the seven known human coronaviruses, MERS-CoV, SARS-CoV-1 and SARS-CoV-2 are the most pathogenic, causing severe, potentially fatal respiratory and cardiovascular symptoms. The emergence of the novel SARS-CoV-2 virus, the cause of the ongoing Coronavirus Disease 2019 (COVID-19) pandemic, has proven to be the greatest public health crisis of the 21st Century. SARS-CoV-2 has a ~30 kb genome that encodes 29 proteins, including 4 structural proteins used in virion assembly, namely the Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S) proteins. The transmembrane Spike protein is a glycoprotein responsible for host-cell binding and viral entry. It is a heterotrimeric complex with two unique subunits. The S1 subunit contains the Receptor Binding Domain, which interacts with Angiotensin-Converting Enzyme 2 as a host-cell receptor, whereas the S2 subunit mediates viral membrane fusion. The S protein is highly immunogenic, with seroconversion in infected individuals typically detected between 5-21 days following the onset of symptoms. BioVision’s SARS-CoV-2 IgM ELISA Kit is an enzyme-linked immunosorbent assay intended for identifying the early immune response to SARS-CoV-2 infection. The assay uses the spike protein S1 subunit as bait to capture anti-SARS-CoV-2 antibodies in diluted plasma or serum samples. Subsequent reaction with an enzyme-labeled anti-human-IgM conjugate and a colorimetric substrate generates color, which is proportional to the amount of anti-S1 antibodies. The presence of anti-SARS-CoV-2 S1 IgM antibodies is determined by comparing the OD450 nm reading of the sample to the OD450 nm reading of the negative control serum. A positive reaction suggests recent infection, as IgM antibodies are the first to appear following exposure and are generally detectable a few days after infection. Positive control serum containing a recombinant human monoclonal anti-S1 IgM antibody is included in the kit for validation. The assay is a quick, easy and accurate method for determination of recent SARS-CoV-2 infection that does not require collection or handling of infectious virus. This kit is a valuable tool to study COVID-19 epidemiology, prevalence and morbidity.


Why buy BioVision Products?
Innovation
Affordability
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.